Fostamatinib Meets Pre-Specified Primary Endpoint in Stage 1 of Autoimmune Hemolytic Anemia (AIHA) Phase 2 Study Oct 03, 2017 7:30am EDT
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) Aug 18, 2017 4:02pm EDT
Rigel Announces Second Quarter 2017 Financial Results and Provides Company Update Aug 01, 2017 4:01pm EDT
Rigel Announces Conference Call and Webcast to Report Second Quarter 2017 Financial Results Jul 25, 2017 7:30am EDT
Rigel Announces Oral Presentation of TAVALISSE™ (fostamatinib disodium) Phase 3 Clinical Data at the European Hematology Association 22nd Annual Congress Jun 22, 2017 4:05pm EDT
FDA Accepts Rigel's New Drug Application for TAVALISSE™ (fostamatinib disodium) for the Treatment of Chronic ITP Jun 19, 2017 7:30am EDT
